RESEARCH TRIANGLE PARK, NC--(Marketwire - June 20, 2011) - Adherex Technologies Inc. (TSX-V: AHX) (PINKSHEETS: ADHXF) (the "Company"), a biopharmaceutical company focused on the development of eniluracil and 5-fluorouracil, today announced that Robert Andrade, Chief Financial Officer, will present at the upcoming OneMed Forum NY 2011 Conference on Thursday, June 23 at 10:45 a.m. at the Roosevelt Hotel, 45 East 45th St. New York, NY.
Except for historical information described in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company's business that could cause actual results to vary, including such risks that regulatory clinical and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company's patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company's products will not be as large as expected, the Company's products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital needs, and its ability to obtain additional funding, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2010. Adherex Technologies, Inc. disclaims any obligation to update these forward-looking statements except as required by law.
For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com